Stay updated with breaking news from Development Contact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Radisson Hotel Group (www.RadissonHotelGroup.com) is proud to announce the signing of Radisson Hotel Middelburg as part of the Group’s ambitious expansion plan in South Africa.
IRVING, Texas, May 11, 2021 /PRNewswire/ -- Caris Life Sciences ®, a leading innovator in molecular science and artificial intelligence (AI) focused on fulfilling the promise of precision medicine, announced an $830 million growth equity round at a post-money valuation of $7.83 billion. With this investment, Caris has raised approximately $1.3 billion in external financing since 2018. This financing represents one of the largest capital raises in precision medicine and includes a diverse syndicate of leading investors. The round was led by Sixth Street, a leading global investment firm mak...
Share this article Share this article CHICAGO, April 9, 2021 /PRNewswire/ -- Waud Capital Partners (Waud Capital or WCP), a leading growth-oriented middle market private equity firm, today announced a new executive partnership with Bales Nelson and Allen Dye to pursue platform investments in the technology-enabled healthcare services and staffing markets. Mr. Nelson and Mr. Dye are highly accomplished healthcare executives each with more than 20 years of management experience and a track record of significant value creation providing technology-enabled services and solutions to health sys...
Caris Life Sciences to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference 2021 News provided by Share this article Share this article IRVING, Texas, Feb. 9, 2021 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence, focused on fulfilling the promise of precision medicine, announced today that David D. Halbert, Chairman and Chief Executive Officer, Brian J. Brille, Vice Chairman, David Spetzler, MS, MBA, Ph.D., President and Chief Scientific Officer and Thomas Parker, Senior Vice President...
Published: Jan 07, 2021 NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ("Kleo") that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo's laboratory facilities located in Science Park in New Haven, Connecticut and formed B...